Tirzepatide: all 180 studies that test it

Page 2 of 2. Open to participants first (96), then studies with results posted, then the rest; newest registration first within each.

• A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection DevicesCompletedNCT05810597Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)CompletedNCT05706506Phase 4Results posted
• A Study of Tirzepatide (LY3298176) in Pediatric Participants With ObesityCompletedNCT05696847Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 DiabetesCompletedNCT05691712Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)CompletedNCT05564039Phase 4Results posted
• Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaCompletedNCT05412004Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)CompletedNCT05024032Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialCompletedNCT04847557Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity DiseaseCompletedNCT04844918Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight LossCompletedNCT04660643Phase 3Results posted
• A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramCompletedNCT04657016Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightCompletedNCT04657003Phase 3Results posted
• A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without MetforminCompletedNCT04537923Phase 3Results posted
• A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using TirzepatideCompletedNCT04407234Phase 1Results posted
• Study of Tirzepatide in Healthy ParticipantsCompletedNCT04311424Phase 1Results posted
• A Study of Tirzepatide in Overweight and Very Overweight ParticipantsCompletedNCT04311411Phase 1Results posted
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesCompletedNCT04255433Phase 3Results posted
• A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes MellitusCompletedNCT04235959Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightCompletedNCT04184622Phase 3Results posted
• A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female ParticipantsCompletedNCT04172987Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04166773Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)CompletedNCT04093752Phase 3Results posted
• A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using TirzepatideCompletedNCT04081337Phase 1Results posted
• A Study of Tirzepatide at Different Injection Sites in Participants With Different Body SizesCompletedNCT04050670Phase 1Results posted
• A Study of Tirzepatide in Participants With Type 2 Diabetes MellitusCompletedNCT04050553Phase 1Results posted
• A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without MetforminCompletedNCT04039503Phase 3Results posted
• A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 DiabetesCompletedNCT03987919Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneCompletedNCT03954834Phase 3Results posted
• A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT03951753Phase 1Results posted
• A Study of Tirzepatide in Participants With Impaired Liver FunctionCompletedNCT03940742Phase 1Results posted
• A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesCompletedNCT03882970Phase 3Results posted
• A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesCompletedNCT03861052Phase 3Results posted
• A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesCompletedNCT03861039Phase 3Results posted
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskCompletedNCT03730662Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney FunctionCompletedNCT03482024Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Healthy ParticipantsCompletedNCT03375463Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 DiabetesCompletedNCT03322631Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesCompletedNCT03311724Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes MellitusCompletedNCT03131687Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)CompletedNCT02759107Phase 1Results posted
• Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesCompletedNCT07834398Phase 3
• Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialCompletedNCT07820111Phase 3
• A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityActive, not recruitingNCT07438444Phase 4
• Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 DrugsActive, not recruitingNCT07303556Not applicable
• A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusActive, not recruitingNCT07299084Phase 1
• The Long COVID Treatment TrialActive, not recruitingNCT07128082Phase 2
• A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityActive, not recruitingNCT06965413Phase 2
• A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightActive, not recruitingNCT06962280Phase 3
• Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVCompletedNCT06935838Phase 2
• Efficacy and Safety of Tirzepatide for Weight ManagementActive, not recruitingNCT06918405Phase 3
• A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityCompletedNCT06916065Phase 1
• A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightActive, not recruitingNCT06914895Phase 3
• A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesWithdrawnNCT06901349Phase 2
• Effect of Tirzepatide on Brown Adipose Tissue in ObesityCompletedNCT06893211Phase 2
• A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy ParticipantsCompletedNCT06890611Phase 1
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)Active, not recruitingNCT06864026Phase 4
• GLP-1s to Enhance Lasting Optimal WeightActive, not recruitingNCT06861439Phase 4
• Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)Active, not recruitingNCT06854614Phase 4
• Bariatric Surgery vs. Semaglutide vs. TirzepatideActive, not recruitingNCT06803888Phase 4
• Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor FunctionsActive, not recruitingNCT06801015Phase 4
• A Study of a Weight Loss Intervention in People With Endometrial CancerActive, not recruitingNCT06751589Early Phase 1
• Tirzepatide for Obesity and Meth Use DisorderCompletedNCT06745128Phase 2
• Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight LossActive, not recruitingNCT06734273Early Phase 1
• A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightActive, not recruitingNCT06643728Phase 2
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During RamadanCompletedNCT06635057Phase 4
• A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesCompletedNCT06603571Phase 2
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightCompletedNCT06588296Phase 3
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightCompletedNCT06588283Phase 3
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothCompletedNCT06534411Phase 3
• Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverTerminatedNCT06515418Phase 2
• A Study of LY3841136 in Japanese Participants With Obesity or OverweightCompletedNCT06297616Phase 1
• Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)Active, not recruitingNCT06191848Phase 4
• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialActive, not recruitingNCT06162715Phase 2/3
• A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingNCT06075667Phase 3
• A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesCompletedNCT06047548Phase 3
• A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityActive, not recruitingNCT06037252Phase 2
• Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With ObesityWithdrawnNCT06009653Phase 4
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityActive, not recruitingNCT05556512Phase 3
• A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedNCT05536804Phase 2
• A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 DiabetesActive, not recruitingNCT05433584Phase 4

← Tirzepatide overview